# A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

> **NCT02215499** · PHASE1 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Narcolepsy, Excessive Daytime Sleepiness

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sodium Oxybate
- **DRUG:** JZP-386

## Key facts

- **NCT ID:** NCT02215499
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215499, "A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02215499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*